Wednesday, November 04, 2015
Tuesday, November 03, 2015
Expert Commentary FAQ in Ovarian Cancer: Unraveling the Risks and Benefits of Antiangiogenic Therapy for Ovarian Cancer Patients
Expert Commentary on Frequently Asked Questions in Ovarian Cancer
Unraveling the Risks and Benefits of Antiangiogenic Therapy for
Ovarian Cancer Patients
Bradley J. Monk, MD, FACS, FACOG
University of Arizona Cancer Center-Ph
Inhaled cannabis for chronic neuropathic pain: an individual patient data meta-analysis - The Journal of Pain
abstract
Highlights
- •Inhaled cannabis appears to provide short term relief from chronic neuropathic pain for one in five to six patients treated.
- •Our novel Bayesian hierarchical model allowed the synthesis of all available patient data from five RCT with disparate design and outcome reporting.
- •Pragmatic long term studies are needed to confirm the safety and effectiveness of inhaled cannabis for chronic neuropathic pain in the community.
Antiemetics: American Society of Clinical Oncology Focused Guideline Update
ASCO open access
INTRODUCTION
The goal of this update is to provide
oncologists, other health care practitioners, patients, and caregivers
with recommendations
regarding the use of netupitant and palonosetron
(NEPA). NEPA was approved by the US Food and Drug Administration (FDA)
in
October 2014 for use in the prevention of acute and
delayed nausea and vomiting associated with initial and repeat courses
of chemotherapy. NEPA is administered orally and
consists of a fixed dose of 300 mg of the neurokinin-1 (NK1) receptor antagonist netupitant combined with 0.50 mg of the 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist palonosetron.....
Subscribe to:
Posts
(
Atom
)
